Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.

about

Fucoidan and Fucosylated Chondroitin Sulfate Stimulate Hematopoiesis in Cyclophosphamide-Induced Mice.Influence of Modified Fucoidan and Related Sulfated Oligosaccharides on Hematopoiesis in Cyclophosphamide-Induced Mice

P2860

Q47129828-9FDB8E5D-1816-4F98-B91F-A51C61A6A4FC Q58742303-416FC07A-363C-4F50-9184-73CAC2591CF0

P2860

Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.

Item

http://www.wikidata.org/entity/Q40785035

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Cyclophosphamide treatment-ind ...... variant CYP450 2C9 genotypes.

@en

type

Item

label

Cyclophosphamide treatment-ind ...... variant CYP450 2C9 genotypes.

@en

prefLabel

Cyclophosphamide treatment-ind ...... variant CYP450 2C9 genotypes.

@en

P1476

Cyclophosphamide treatment-ind ...... variant CYP450 2C9 genotypes.

@en

P2093

Frank Moosig

http://www.w3.org/2001/XMLSchema#string

Jan Phillip Bremer

http://www.w3.org/2001/XMLSchema#string

Julia Ulrike Holle

http://www.w3.org/2001/XMLSchema#string

Peter Lamprecht

http://www.w3.org/2001/XMLSchema#string

Sierk Haenisch

http://www.w3.org/2001/XMLSchema#string

Stefan Wieczorek

http://www.w3.org/2001/XMLSchema#string

P2860

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Antimycotic drug discovery in the age of genomics.

Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

EULAR recommendations for the management of primary small and medium vessel vasculitis.

Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

P304

367-374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.15.176

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jan H Schirmer

Ingolf Cascorbi

P577

2016-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

295244721

http://www.w3.org/2001/XMLSchema#string

P698

26894931

http://www.w3.org/2001/XMLSchema#string

Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.

about

P2860

P2860

Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698